Oxidative status imbalance in patients with metabolic syndrome: Role of the myeloperoxidase/hydrogen peroxide axis by Da Fonseca, L.J.S. et al.
Clinical Study
Oxidative Status Imbalance in Patients with Metabolic
Syndrome: Role of the Myeloperoxidase/Hydrogen Peroxide Axis
Lucas José Sá da Fonseca,1 Valéria Nunes-Souza,1,2,3 Glaucevane da Silva Guedes,1,2,4
Glauber Schettino-Silva,1 Marco Antônio Mota-Gomes,5 and Luíza Antas Rabelo1,2,3
1 Laborato´rio de Reatividade Cardiovascular, Setor de Fisiologia e Farmacologia, Instituto de Cieˆncias Biolo´gicas e da Sau´de (ICBS),
Universidade Federal de Alagoas (UFAL), Avenida Lourival Melo Mota, s/n, Cidade Universita´ria, 57072-900 Maceio´, AL, Brazil
2 Instituto Nacional de Cieˆncia e Tecnologia em NanoBiofarmaceˆutica (N-BIOFAR), Avenida Antoˆnio Carlos, s/n, Pampulha,
Belo Horizonte, MG, Brazil
3Max-Delbru¨ck-Center for Molecular Medicine, Robert-Ro¨ssle-Strße 10, 13125 Berlin, Germany
4 Faculdade de Nutric¸a˜o (FANUT), Universidade Federal de Alagoas (UFAL), Avenida Lourival Melo Mota, s/n, Cidade Universita´ria,
57072-900 Maceio´, AL, Brazil
5 Centro de Pesquisas Cl´ınicas do Hospital do Corac¸a˜o de Alagoas (HCOR-AL), Avenida Ariosvaldo Pereira Cintra 152,
Gruta de Lourdes, 57052-580 Maceio´, AL, Brazil
Correspondence should be addressed to Luı´za Antas Rabelo; luizaa.rabelo@gmail.com
Received 23 May 2014; Revised 17 August 2014; Accepted 11 September 2014; Published 15 October 2014
Academic Editor: Qingping Feng
Copyright © 2014 Lucas Jose´ Sa´ da Fonseca et al.This is an open access article distributed under theCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in anymedium, provided the originalwork is properly cited.
The present study evaluated the cardiometabolic and redox balance profiles in patients with Metabolic Syndrome compared to
apparently healthy individuals, and the participation of themyeloperoxidase/hydrogen peroxide axis in systemic lipid peroxidation.
Twenty-four patients with Metabolic Syndrome and eighteen controls underwent a full clinical assessment. Venous blood samples
were collected for general biochemical dosages, as well as for the oxidative stress analyses (superoxide dismutase, catalase, and
arginase activities; and lipid peroxidation, myeloperoxidase activity, nitrite, and hydrogen peroxide concentrations in plasma).
Arterial stiffness was assessed by radial artery applanation tonometry. Plasma lipid peroxidation, erythrocyte superoxide dismutase
activity, myeloperoxidase activity, and hydrogen peroxide concentrations were shown to be increased in Metabolic Syndrome
patients, without significant differences for the other enzymes, plasma nitrite concentrations, and arterial stiffness. Linear regression
analysis revealed a positive and significant correlation between lipid peroxidation and myeloperoxidase and also between this
enzyme and hydrogen peroxide. In contrast, such correlation was not observed between lipid peroxidation and hydrogen peroxide.
In summary, Metabolic Syndrome patients exhibited evident systemic redox imbalance compared to controls, with the possible
participation of the myeloperoxidase/hydrogen peroxide axis as a contributor in lipid peroxidation.
1. Introduction
Cardiovascular diseases represent the leading cause of death
worldwide and may result from the association of different
cardiometabolic risk factors [1]. When such factors simul-
taneously cluster in the same individual, they contribute to
the establishment ofMetabolic Syndrome (MetS), a condition
characterized by the combination of increased blood pressure
and glycemic levels, dyslipidemia, and abdominal obesity
[2–4], which directly increases the risk of cardiovascular
disease in its carriers [1, 2]. Indeed, the MetS participates
in various pathological metabolic processes, with possible
negative outcomes on the general biochemical profile [5],
redox balance [4–6], and arterial function [1, 7].
When considering the MetS diagnostic parameters, a
huge body of evidence points to their relation with the
oxidative stress [4, 5, 8]. The latter, also known as redox
imbalance, is characterized by a condition inwhich the excess
of reactive oxygen and nitrogen species (RONS) compro-
mises or even surpasses the action of endogenous antioxidant
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systems, either for increase in prooxidants, such as RONS,
or for decreased antioxidant defense [9]. The oxidative stress
implies pleiotropic toxic effects on cellular metabolism [4,
10], with potential damage to different organic systems [5,
11], especially in the vasculature [10, 12]. Concerning the
association between oxidative stress and the MetS, literature
reports are not consensual when it comes to the pattern of
redox balance in patients presenting with MetS [6, 8, 13].
Myeloperoxidase (MPO), a heme peroxidase abundantly
expressed in leukocytes, is a central enzyme in innate host
defense [14, 15]. Primarily stored in cytoplasmic granules
[16], MPO may be released to the extracellular compart-
ment after phagocyte activation [17, 18]. Using hydrogen
peroxide (H
2
O
2
) as a cosubstrate, MPO participates in the
formation of different oxidants, amongwhich are hypohalous
acids [16]. Despite its beneficial effects related to leukocyte-
mediated protection against pathogens, its excessive activity
may imply tissue damage through oxidant production [15],
being involved in chronic inflammatory conditions [14],
among which are atherosclerosis and coronary artery disease
[19], and also promoting endothelial dysfunction [20]. In this
respect, however, even though several lines of evidence point
to the association between the parameters related to theMetS
and oxidative stress [12, 21, 22], the in-depth mechanisms
involved in the pathophysiology of the MetS, particularly
those related to its components, oxidative stress, and arterial
function, still remain poorly understood. Based upon this
scenario, the present work aims to assess the oxidative stress
profile in patients withMetS and their arterial status, and also
to evaluate a possible pathway through which oxidative stress
markers may contribute to systemic lipid peroxidation.
2. Materials and Methods
2.1. Subjects. For this case-control study, a total of twenty-
four patients with MetS and eighteen apparently healthy sub-
jects were nonprobabilistically selected from the ambulatory
of Endocrinology at the Teaching Hospital of the Federal
University of Alagoas and from the adjacent community,
respectively. Patients were paired for age, sex, tobacco use,
dietary habits, and socioeconomic status. The steps from
selection until the clinical and biochemical assessments are
presented in Figure 1. The study protocol was approved by
the Ethical Committee of the Federal University of Alagoas
(Protocol number 010501/2009-91) and was in accordance
with the principles outlined in the Declaration of Helsinki.
All subjects gave written informed consent before carrying
out the procedures.
The diagnosis of MetS was made based on the criteria
defined by the International Diabetes Federation [23]. For
both groups, exclusion criteria were age <30 or >65 years,
patients taking antioxidant supplements, individuals present-
ing abnormalities which precluded the arterial assessment
using radial artery applanation tonometry (e.g., patients with
known arrhythmia, using pacemakers and those in which the
left radial artery palpation could not be properly performed),
pregnant or lactating women, patients undergoing hormone
replacement therapy, abuse of alcohol, overt cerebrovascular,
kidney or liver diseases, malignancies, as well as those who
refused to participate in the study.
2.2. Clinical Assessment and Anthropometry. Initially,
patients underwent a full anamnesis and physical
examination. For brachial blood pressure measurements,
a validated oscillometric device was used (Microlife,
Widnau, Switzerland), with the cuff properly adapted to
arm circumference. Three consecutive measures were taken,
separated by one-minute interval each.The last twomeasures
were averaged in order to obtain the mean for SBP and DBP.
Heart rate (HR) was obtained simultaneously, with the
last two measures averaged. Mean arterial pressure (MAP)
was calculated according to the formula: MAP = (SBP +
2DBP)⋅3−1. Pulse pressure (PP) was obtained by subtraction
between SBP and DBP.
Body weight was assessed using a precision digital scale
(Filizola, Sa˜o Paulo, Brazil) to the nearest 0.1 kg, with the
individuals in standing position, barefoot and wearing light
clothes. Height was measured at the highest head point to the
nearest 0.5 cm, with a stadiometer coupled to the scale and
the head in anatomical position. Body mass index (BMI) was
defined as the ratio between the body weight and the square
of the height, expressed in kg⋅m−2.
Waist circumference (WC, to the nearest 0.5 cm) was
measured using a heavy-duty inelastic fiberglass tape (Car-
diomed, Curitiba, Brazil) placed horizontally and tension free
immediately over the skin at the midpoint between the last
rib and the iliac crest, with measurements taken at the end of
expiration. Neck circumference (NC) was assessed with the
head in anatomical position, and the fiberglass tape placed
right above the superior margin of the laryngeal prominence,
parallel to the horizontal plane. Hip circumference (cm) was
measured taking as reference the largest circumference on the
hip anatomy, and waist-to-hip ratio (WHR) was then calcu-
lated. All anthropometric measurements were performed in
the morning by an only physician previously trained.
2.3. Noninvasive Assessment of the Arterial Function. For
noninvasively assessing the arterial function, the method of
radial artery applanation tonometry was used, as described
elsewhere [24]. All results were expressed as the average of
the three measures captured by the sensor. The procedures
were performed by a previously trained investigator broadly
familiarized with the method.
2.4. Blood Samples Collection and General Biochemical Profile.
For the biochemical analysis, patients underwent peripheral
venous blood collection from an antecubital vein after a 12-
hour overnight fasting. Immediately after, samples destined
to the determination of general biochemical profile were pro-
cessed according to standard laboratory techniques. Analytes
for assessing the redox state were rapidly put in ice bath (4∘C),
being centrifuged at 1600 g for 10 minutes (Fanem, Sa˜o Paulo,
Brazil) to separate plasma fromblood cellular elements. Next,
plasma and erythrocyte samples were aliquoted and stored at
−80∘C until analysis.
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Figure 1: Study flow-chart. MetS: Metabolic Syndrome.
2.5. Nonesterified Fatty Acids (NEFA) in Plasma. The NEFA
quantification in plasma samples was assayed using a com-
mercial kit (Wako Chemicals GmbH, Neuss, Germany),
according to the manufacturer’s protocol, with adaptations
for microplate (Thermo Fisher Scientific, Vantaa, Finland).
The results were expressed in mmol⋅L−1.
2.6. Fasting Insulin in Plasma. For quantitative insulin detec-
tion in plasma, a commercial ELISA kit was used (Millipore,
Missouri, USA), following the manufacturer’s instructions. A
standard curvewas used to determine insulin concentrations,
with the results expressed in mU⋅L−1.
2.7. Assessment of Insulin Resistance. The degree of insulin
resistance was estimated using the mathematical model
HOMA-IR (Homeostasis Model Assessment − Insulin Resis-
tance) index and calculated as follows: HOMA-IR = [fasting
insulin (𝜇U⋅L−1) × fasting glucose (mmol⋅L−1)]/22.5 [25].
Values were expressed in 𝜇U⋅L−1/mmol⋅L−1. HighHOMA-IR
values indicate a state of insulin resistance, while lowHOMA-
IR values are associated with better insulin sensitivity.
2.8. Estimation of the Glomerular Filtration Rate. Estimated
glomerular filtration rate (eGFR) was calculated using the
simplified MDRD (Modification of Diet in Renal Disease)
formula, as follows: 186× plasma creatinine−1.154 × age−0.203 ×
1.212. For women, results were further multiplied by the
constant 0.742 [26].
2.9. Lipid Peroxidation in Plasma. The lipid peroxidation in
plasma was quantified based on the protocol described by
Ohkawa et al. [27], with slight adaptations, for determin-
ing the Thiobarbituric Acid Reactive Substances (TBARS),
among which malondialdehyde (MDA) figures as the most
representative one. Absorbance was read in a microplate
reader (Thermo Fisher Scientific, Vantaa, Finland), at wave-
lengths of 532 nm and 600 nm. The dosages were performed
in duplicate and TBARS values were normalized by total
protein concentration in plasma [28], and expressed as
𝜇M⋅[Protein]mg⋅mL−1.
2.10. Erythrocyte Lysates and Measurement of Hemoglobin
Concentrations. After thawing in ice bath (4∘C), 250𝜇L
of erythrocyte samples were taken for hemolysis, being
aliquoted and stored at −80∘C, until the redox analyses were
performed. Hemoglobin (Hb) concentrations in erythrocyte
lysates were measured using a commercial kit (Labtest, Belo
Horizonte, Brazil), according to the manufacturer’s protocol.
2.11. Total Superoxide Dismutase (SOD) Activity in Erythro-
cytes and in Plasma. Superoxide dismutase (SOD) activity
was determined in erythrocyte lysates and in plasma, being
read in microplate (Nunc, Roskilde, Denmark), using a com-
mercial kit (Fluka, Sigma-Aldrich, St. Louis, USA), according
to the manufacturer’s protocol, at a wavelength of 450 nm
(Thermo Fisher Scientific, Vantaa, Finland). Values were nor-
malized by Hb concentrations and expressed in IU⋅mgHb−1
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in erythrocytes and by the total protein concentration [28] in
plasma, with results expressed in IU⋅mgProtein−1.
2.12. Catalase Activity in Erythrocytes and in Plasma. Cata-
lase activity was measured in erythrocyte samples and in
plasma inmicroplates (Nunc, Roskilde, Denmark), according
to the protocol described by Xu et al. [29] and expressed in
IU⋅mgHb−1 in erythrocytes. For catalase activity in plasma,
samples were directly plated in the wells, without dilution,
before the reagent addition. Values were normalized by total
protein concentration [28] and the enzyme activity, expressed
as IU⋅mgProtein−1.
2.13. Hydrogen Peroxide (H
2
O
2
) Concentrations in Plasma.
The quantification of plasma H
2
O
2
levels was performed by
fluorescence (Tecan 200 Infinite, Ma¨nnedorf, Switzerland),
with a commercial kit (Ultra Amplex Red Hydrogen Perox-
ide/Peroxidase Assay kit, Invitrogen, Paisley, UK), accord-
ing to the manufacturer’s instructions. In the presence of
peroxidase (horseredish peroxidase, HRP), the Amplex Red
reagent stoichiometrically reacts with H
2
O
2
to form a red-
fluorescent oxidation product, resorufin. A standard curve
of H
2
O
2
was prepared, with concentrations ranging from
0 to 10 𝜇M. Next, 50 𝜇L from the curve points or from
the samples were plated in duplicate, with the addition of
50𝜇L of the reagent/HRP solution to start the reaction.
Finally, the black microplates (Nunclon Surface, Thermo
Fisher Scientific, Vantaa, Finland) were incubated at room
temperature for 120 minutes, protected from light and read
at wavelengths of 530 and 590 nm, respectively, related to
excitation and emission.
2.14. Myeloperoxidase (MPO) Activity in Plasma. Similarly
to the determination of H
2
O
2
levels, MPO activity in
plasma samples was performed using the Ultra Amplex
Red Hydrogen Peroxide/Peroxidase Assay kit (Invitrogen,
Paisley, UK), according to the manufacturer’s instructions.
A standard curve was prepared, with MPO concentrations
ranging from 0.0312 to 1.0UI⋅mL−1 (Sigma, St. Louis, USA).
Then, 50𝜇L of the curve points or from the samples were
plated, with the addition of the Amplex Red/H
2
O
2
working
solution to start the reaction. Next, samples were incubated
at room temperature for 150 minutes, protected from light.
Finally, fluorescence was measured in a spectrofluorometer
(Tecan 200 Infinite, Ma¨nnedorf, Switzerland), using black
microplates (Nunclon Surface, Thermo Fisher Scientific,
Vantaa, Finland) at the wavelengths of 530 and 590 nm for
excitation and emission, respectively.
2.15. Plasma Levels of Nitrite. The quantification of plasma
nitrite concentrations was performed based on the proto-
col described by Misko et al. [30], with adaptations for
microplates. This fluorimetric assay is based on the reaction
between nitrite and the compound 2,3-diaminonaphthalene
(DAN), originating 2,3-diaminonaphthotriazole. Initially,
plasma samples were filtered using a 10 dKamolecular weight
filter (Millipore, Missouri, USA). Then, using black 96-
well microplates (Nunclon Surface,Thermo Fisher Scientific,
Vantaa, Finland), to 50 𝜇L of each sample (in duplicate)
were added 100 𝜇L of deionized water. Next, 10 𝜇L of DAN
(0.05mg⋅mL−1 in HCl 0.62M) were added and mixed
immediately, with DAN always protected from light. After
incubation at 20∘C for 10 minutes, the reaction was stopped
by the addition of 5𝜇L of NaOH (2.8M). The compound
formed was quantified in a spectrofluorometer (Tecan 200
Infinite, Ma¨nnedorf, Switzerland), at 365 nm and 410 nm for
excitation and emission, respectively. Nitrite concentrations
were calculated based on a standard curve of nitrite.
2.16. Arginase Activity in Erythrocytes and in Plasma.
Arginase activity was determined using a colorimetric
method, as previously described [31], with adaptations for
microassays. Briefly, erythrocyte lysates were dissolved in
PBS 1 : 20 (v : v) and homogenized under cooling. Next, 50𝜇L
from the solution were incubated with 75𝜇L of a Tris-
HCl (50mmol⋅L−1 plus 10mmol MnCl
2
; pH 7.5) solution
supplemented with manganese chloride (10mmol⋅L−1) at
60∘C in an incubator during 10 minutes. After this, the
reactionwas initiated by the addition of 50𝜇L of the substrate
L-arginine (100mmol⋅L−1) and processed at 37∘C for 1 hour.
At the end of this step, 400 𝜇L of an acid solution were
added in order to stop the reaction.The reagent 𝛼-isonitroso-
propiophenone (25𝜇L; 9% in EtOH) was then added to
the mixture, following another reaction for 45 minutes
at 100∘C. Finally, samples were incubated in the dark at
room temperature for 10minutes before reading. Absorbance
was measured at 540 nm in a microplate reader (Thermo
Fisher Scientific, Vantaa, Finland). Data were normalized
according to hemoglobin concentrations, and enzyme activ-
ity was expressed in mmol/min/mL⋅mgHb−1. For assessing
the arginase activity in plasma, samples were not diluted
but directly plated in the wells, with the other procedures
similar to those applied during the determination of activity
in erythrocytes. Data were normalized according to the
total protein concentrations [28], and enzyme activity was
expressed in mmol/min/mL⋅mgProtein−1.
2.17. Statistics. Data were analyzed using GraphPad Prism,
version 5.00 (San Diego, CA, USA), and normality was tested
applying the Shapiro-Wilk test. For continuous variables
with normal distribution, the Student’s 𝑡-test was used. For
variables not presenting Gaussian distribution, the non-
parametric Mann-Whitney U test was applied. Continuous
variables are presented as mean ± standard deviation (SD)
and categorical variables, in percentage. Linear regression
analysis was also performed and results were considered
significant if 𝑃 < 0.05.
3. Results
3.1. Sample Characterization. The sample characterization
evidenced the predominance of female patients in both
groups (Table 1). No significant differences were observed for
age and height. As expected, for theMetS individuals, weight,
BMI, WC, WHR, and NC were increased compared to the
controls (Table 1). Regarding drug therapy, 18 (75%) among
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Table 1: General, anthropometric, cardiovascular, and biochemical characteristics of participants included in the study.
Control group
(𝑛 = 18)
MetS group
(𝑛 = 24)
a 𝑃 values
General and anthropometric characteristics
Gender D (𝑛/%)5/27.77
C (𝑛/%)
13/72.23
D (𝑛/%)
6/25
C (𝑛/%)
18/75
Smoking 1/5.56 2/8.33
Age (years)b 45.50 ± 7.45 50.17 ± 8.27 NS
Weight (kg)c 68.63 ± 11.04 79.86 ± 17.83∗ 0.02
Height (m)c 1.60 ± 0.10 1.58 ± 0.10 NS
BMI (kg⋅m−2)c 26.69 ± 3.27 32.09 ± 7.10∗∗ 0.0073
WC (cm)b 87.89 ± 7.65 103.30 ± 13.96∗∗∗ 0.0001
WHRb 0.83 ± 0.06 0.90 ± 0.09∗∗ 0.0042
NC (cm)c 34.92 ± 3.24 37.46 ± 5.99∗ 0.03
Cardiovascular parameters
SBP (mmHg)c 116.60 ± 9.18 134.00 ± 15.36∗∗∗ 0.0007
DBP (mmHg)b 75.44 ± 5.92 81.75 ± 8.53∗∗ 0.0078
MAP (mmHg)b 89.16 ± 5.94 99.16 ± 9.41∗∗∗ 0.0003
PP (mmHg)b 41.14 ± 8.51 52.23 ± 12.24∗∗ 0.0021
HR (bpm)b 72.58 ± 13.47 70.94 ± 12.68 NS
Glycemic profile, insulinemia, and insulin resistance
Fasting glucose (mg⋅dL−1)c 80.11 ± 6.67 127.80 ± 64.10∗∗∗ <0.0001
HbA1c (%)c 4.99 ± 0.26 6.50 ± 1.66∗∗∗ <0.0001
Insulinemia (mU⋅L−1)c 8.95 ± 4.44 13.60 ± 6.21∗∗∗ <0.0001
HOMA-IR (𝜇U⋅mL−1)c 1.80 ± 1.06 4.58 ± 3.95∗∗∗ <0.0001
Lipid profile
Total cholesterol (mg⋅dL−1)b 182.70 ± 29.83 225.60 ± 53.86∗∗ 0.0041
Triglycerides (mg⋅dL−1)c 81.39 ± 22.91 180.90 ± 110.30∗∗∗ <0.0001
HDL (mg⋅dL−1)c 49.17 ± 5.76 48.63 ± 15.08 NS
LDL (mg⋅dL−1)b 117.80 ± 28.78 139.70 ± 41.54 NS
VLDL (mg⋅dL−1)c 15.57 ± 4.47 36.18 ± 22.06∗∗∗ <0.0001
TG/HDL ratioc 1.69 ± 0.56 4.01 ± 2.48∗∗∗ <0.0001
TC/HDL ratioc 3.76 ± 0.72 4.81 ± 1.07∗∗ 0.0008
NEFA (mmol⋅L−1)b 0.32 ± 0.10 0.36 ± 0.09 NS
Renal function parameters
Urea (mg⋅dL−1)b 25.17 ± 7.13 29.58 ± 7.50 NS
Creatinine (mg⋅dL−1)b 0.77 ± 0.15 0.90 ± 0.18∗ 0.0207
eGFR (mL/min/1.73m2)b 119.00 ± 27.12 95.23 ± 21.92∗∗ 0.0031
Others parameters
WBC count (cells/mm3)b,d 6617 ± 1659 6400 ± 1744 NS
Neutrophils (cells/mm3)b,d 3934 ± 1553 3585 ± 1132 NS
Neutrophils (%)c,d 57.72 ± 11.09 55.71 ± 6.79 NS
Uric acid (mg⋅dL−1)b 3.31 ± 0.80 4.11 ± 1.14∗ 0.0150
AST (U⋅mL−1)c 21.50 ± 8.05 32.63 ± 20.83∗ 0.0127
ALT (U⋅mL−1)c 22.33 ± 9.77 46.88 ± 35.96∗∗∗ 0.0006
AST/ALT ratiob 1.01 ± 0.29 0.78 ± 0.23∗∗ 0.0063
hs-CRP (mg⋅L−1)c 2.77 ± 2.30 3.59 ± 3.94 NS
Values are expressed as mean ± standard deviation. aFor LDL-c levels in the MetS group, 𝑛 = 23 because one patient exhibited triglyceride levels greater
than 400mg⋅dL−1, thus impairing the determination of LDL-c levels. For the other parameters assessed in the MetS group, 𝑛 = 24. bStudent’s 𝑡 Test. cMann-
Whitney𝑈Test. dValues obtained from peripheral venous blood samples. NS: nonsignificant. ALT: alanine aminotransferase; AST: aspartate aminotransferase;
BMI: body mass index; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; HbA1c: glycated hemoglobin; HDL: high density lipoprotein
cholesterol; HOMA-IR: homeostasis model assessment-insulin resistance; HR: heart rate; hs-CRP: high-sensitivity C-reactive protein; LDL: low density
lipoprotein; MAP: mean arterial pressure; NC: neck circumference; NEFA: non-esterified fatty acids; PP: pulse pressure; SBP: systolic blood pressure; TC:
total cholesterol; TG: triglycerides; VLDL: very low density lipoprotein; WBC: white blood cell; WC: waist circumference; WHR: waist-to-hip ratio. ∗𝑃 < 0.05;
∗∗
𝑃 < 0.01; ∗∗∗𝑃 < 0.0001.
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Table 2: Medications used by patients presenting with MetS.
Medications (patients under use/total) %
𝛽-blockers 5/24 20.83
Diuretics 6/24 25.00
ACE inhibitors 5/24 20.83
Angiotensin AT1 receptor
antagonist 4/24 16.66
Calcium channel blockers 4/24 16.66
Aldosterone antagonist 1/24 4.16
Metformin 6/24 25.00
Glibenclamide 4/24 16.66
Statins 3/24 12.50
NPH insulin 1/24 4.16
Values do not sum 100% because some patients were under combined
pharmacological treatment. ACE: angiotensin converting enzyme.
all MetS patients were under regular use of medications for
treating hypertension, dysglycemia/type 2 diabetes mellitus,
or dyslipidemia (Table 2). The participants in the control
group were not under use of any pharmacological treatment.
3.2. A Hypertensive Pattern and a Marked Imbalance in Glu-
cose Profile Were Found in MetS Patients, despite the Pharma-
cological Treatment. For the cardiovascular parameters, SBP,
DBP, PP, and MAP were significantly higher in MetS patients
than observed in the controls (Table 1). For HR, however, no
difference was identified between groups (Table 1). Results
concerning the glucose profile evidenced both higher fasting
glucose and HbA1C levels in MetS patients compared to the
controls (Table 1). Fasting insulinemia levels and the degree
of insulin resistance were also increased in MetS patients
(Table 1).
3.3. Significant Dyslipidemia Accompanied the Dysglycemia in
MetS Patients. MetS patients presented significant dyslipi-
demia, with higher levels for total cholesterol, triglycerides,
and VLDL cholesterol compared to the controls (Table 1).
Furthermore, MetS individuals presented higher values for
triglycerides/HDL cholesterol and total cholesterol/HDL
cholesterol ratios, without significant differences for plasma
concentrations of HDL cholesterol, LDL cholesterol, and
NEFA (Table 1).
3.4. MetS Patients Displayed Diminishment in Renal Func-
tion. When considering the parameters for renal assessment
between groups, no significant difference for urea concen-
tration in plasma was observed. Nevertheless, MetS patients
showed decreased renal function compared to the controls,
as observed by increased creatinine levels and lower eGFR
(Table 1).
3.5. MetS Patients Presented Elevated Uricemia and Liver
Enzymes, without Changes in Neutrophil Count and in
High-Sensitivity C-Reactive Protein Levels. MetS individuals
showed higher uric acid and AST and ALT concentrations
in plasma, compared to the controls. Also, a reduction in the
AST/ALT ratio was observed in theMetS group. However, for
the hs-CRP levels, white blood cell count, and neutrophils, no
differences between groups were observed (Table 1).
3.6.TheLack ofDifference betweenGroups for Arterial Stiffness
and Nitrite Concentrations in Plasma Was Accompanied by
Similar Arginase Activity. Results for the arterial stiffness
assessment did not show significant difference between
groups for theAI (Figure 2(a)).The lack of difference between
groups was also observed when quantifying the nitrite levels
in plasma (Figure 2(b)). For the arginase activity, no differ-
ences were observed between groups, neither in erythrocytes
(Figure 2(c)), nor in plasma (Figure 2(d)).
3.7. Increased Erythrocyte SODActivityWas Not Accompanied
by Changes in Catalase Activities. For total SOD activity
in plasma, no significant difference was observed between
groups (Figure 3(a)). For total SOD in erythrocytes, however,
a significantly higher activity was found in MetS individuals
(Figure 3(b)). Nevertheless, for the catalase activities, no sig-
nificant differences between groups were identified (Figures
3(c) and 3(d)).
3.8. Augmented H
2
O
2
Concentrations and MPO Activity May
Contribute to Increased Lipid Peroxidation in Plasma. The
analysis of H
2
O
2
in plasma evidenced higher concentrations
in patients with MetS compared to the controls (Figure 4(a)).
In the same direction of the observation for H
2
O
2
concen-
trations, MPO activity in plasma was found to be increased
in MetS individuals (Figure 4(b)). The assessment of lipid
peroxidation in plasma showed a greater state of systemic
redox imbalance in MetS patients, as observed by the
increased MDA concentrations in such group compared to
the controls (Figure 4(c)). Linear regression analyses revealed
positive and significant correlations between two MetS com-
ponents (WC and fasting glucose) and MPO (Figures 5(f)
and 5(g), resp.) and also between fasting insulin and MPO
(Figure 5(h)). For the other MetS components and LDL-c,
no significant correlations were observed withMPO (Figures
5(a)–5(e)). For the oxidative stress markers MDA, MPO, and
H
2
O
2
, significant correlations were found betweenMDA and
MPO and also between MPO and H
2
O
2
but not between
MDA and H
2
O
2
(Figure 6).
4. Discussion
The main findings of the present work point to the possible
action of MPO on its cosubstrate, H
2
O
2
, amplifying the
systemic lipoperoxidation, being unlikely the direct partic-
ipation of such radical in this process, in the considered
sample.
When assessing the oxidative status, a significant redox
imbalance in the MetS group was observed compared to the
controls, as identified by increased lipid peroxidation in the
former. In this regard, a large body of evidence points to
obesity as a critical determinant of systemic oxidative stress
in humans [4, 32]. Thus, it is plausible to consider obesity,
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Figure 2: (a) Augmentation Index (AI), (b) nitrite concentrations, and ((c) and (d)) arginase activities in patients with Metabolic Syndrome
(MetS; 𝑛 = 24) and controls (𝑛 = 18). Student’s 𝑡-test for AI and nitrite concentrations. Mann-Whitney 𝑈 test for arginase activities.
particularly that observed by increased WC, as a contributor
for the augmented lipoperoxidation levels inMetS patients in
this study. Indeed, we found a significant positive correlation
between WC and MPO activity (Figure 5(f)). In line with
these observations, Fujita et al. [33], in a case-control study,
found increased levels of urinary 8-epi-prostaglandin F
2
(a marker of systemic oxidative stress) in MetS carriers.
Furthermore, such oxidativemarkerwas shown to be strongly
correlated with visceral obesity [33].
A significant dysglycemia, with increased insulin resis-
tance, was another prominent feature of MetS patients in
the present study. In this regard, our group showed that the
increase in lipid peroxidation was positively correlated with
fasting glucose and HbA1C in diabetic patients [34]. These
statements, together with the significant positive correlations
between fasting glucose/fasting insulin and MPO activity
(Figures 5(g) and 5(h)) in the current study, reinforce the
probable participation of dysglycemia in the maintenance of
the environment of redox imbalance in patients with MetS.
Our findings for lipid peroxidation are in line with
those of Demircan et al. [13] and Armutcu et al. [8], as
both groups observed, in case-control studies, increased
plasma MDA levels in MetS individuals. In opposition to
these findings, a case-control study with MetS patients by
Sa´nchez-Rodr´ıguez et al. [6] failed to show statistically sig-
nificant differences between groups for lipoperoxidation.The
apparent discrepancy between the aforementioned studies
highlights the complexity with which the MetS presents
itself in the clinical setting, so that it seems reasonable
to consider other possible contributors for the state of
lipid peroxidation identified, such as the accuracy of the
methodologies used for estimating the degree of oxidative
stress, age, the presence of comorbidities, and dietary habits
[35]. We also found higher erythrocyte SOD activity in MetS
patients. Indeed, SOD represents a first-line endogenous
antioxidant defense, converting ∙O
2
− to O
2
and H
2
O
2
[36,
37]. Olusi, while studying the erythrocyte Cu-ZnSODactivity
in obese individuals, observed reduced enzyme activity in
these individuals, compared to counterparts without obesity.
Viroonudomphol et al. [38], in turn, highlighted that SOD,
by an adaptive response, may present augmented activity
in states of increased lipoperoxidation, as a compensatory
means tomitigate redox imbalance. Considering these obser-
vations, it is likely that the increased erythrocyte SOD activity
found in the current study occurred as a compensatory
response for opposing the increased lipid peroxidation.
Following the action of SOD on ∙O
2
−, H
2
O
2
may be
converted to H
2
O and O
2
under the actions of catalase or
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Figure 3: ((a) and (b)) Superoxide dismutase (SOD) and ((c) and (d)) catalase activities in patients with Metabolic Syndrome (MetS; 𝑛 = 24)
and controls (𝑛 = 18). Student’s 𝑡-test for SOD and catalase in plasma.Mann-Whitney𝑈 test for SOD and catalase in erythrocytes. ∗∗𝑃 < 0.01.
glutathione peroxidase (GPx) [10, 36]. Hence, in the present
study, increased SOD activity was accompanied by aug-
mented levels of H
2
O
2
, a substrate for catalase. However, no
significant changes in catalase activities were observed. In
view of the fact that GPx represents an antioxidant enzyme
not assessed in our sample, it is not possible to exclude its
participation in degrading H
2
O
2
.
MetS patients in the present study exhibited higher
plasma MPO activity, compared to controls. This enzyme is
already described as an important cardiovascular risk factor,
capable of potentiating the oxidative effects of its cosubstrate,
H
2
O
2
[20].
In order to study the possible contribution of MPO
activity and H
2
O
2
concentrations in the determination of
lipid peroxidation, linear regression analysis was performed,
with the observation of a positive correlation between MPO
activity and MDA plasma levels but not between H
2
O
2
concentrations andMDAplasma levels (Figure 6).These data
suggest the direct participation of MPO in increasing lipid
peroxidation, with this fact not holding true for H
2
O
2
. Inter-
estingly, the occurrence of a significant positive correlation
between MPO activity and H
2
O
2
(Figure 6) finally suggests
that one of the pathways responsible for inducing lipid
peroxidation seems to be strongly dependent on the action
of MPO on its cosubstrate, H
2
O
2
, being unlikely the direct
participation of such radical in this process. Considering the
potential consumption of H
2
O
2
by MPO, one could expect
to observe an inverse correlation between such variables, as
the increased MPO activity could respond for reduced H
2
O
2
levels, but our data point to a direct correlation instead. This
finding may be due to the fact that the augmentation in
MPO activity and the H
2
O
2
consumption are not occurring
in a proportional manner, with the cosubstrate production
surpassing its diminishment by MPO. The activity of this
enzyme, albeit elevated in MetS patients, was not increased
enough to determine reduced H
2
O
2
levels, the latter propor-
tionally higher as a consequence of the overt environment of
redox imbalance observed.
After activation, by a process of degranulation, neu-
trophils release MPO, becoming depleted of this enzyme
[18, 39].Thus, despite the fact that no difference was observed
between groups for neutrophil count (Table 1), it is reasonable
to consider that elevated MPO activity in plasma samples
of MetS patients may come from activated leukocytes. In
addition, insulin resistance is responsible for augmenting
the levels of proinflammatory mediators [40]. Furthermore,
adipocytes, particularly in obese individuals, release inflam-
matory cytokines which compromise the insulin signaling
Oxidative Medicine and Cellular Longevity 9
Control MetS
0
500
1000
1500 Plasma
H
2
O
2
(n
M
/p
ro
te
in
 m
g·
m
L−
1
)
∗∗
(a)
Plasma
Control MetS
0
1
2
3
4
5
M
PO
 ac
tiv
ity
 (U
I·m
L−
1
/p
ro
te
in
 m
g·
m
L−
1
)
∗∗
(b)
Plasma
Control MetS
0
3
6
9
12
15
[M
D
A
] (
𝜇
M
/p
ro
te
in
 m
g·
m
L−
1
)
∗∗∗
(c)
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[41]. Both of these factors (insulin resistance and central
obesity) were found in MetS patients, but no differences
were observed between groups for the marker of systemic
inflammation hs-CRP.However, chronic inflammation is also
associated with increased expression of MPO [14]. Literature
highlights the association between proinflammatory medi-
ators and the pathogenesis of the MetS, once dysregulation
in inflammatory responses in the muscle and liver may be
observed in the course of that syndrome [42]. Thus, the lack
of difference for hs-CRP between groups and the significant
increase in plasma MPO activity in the case group point to
the potential use of such enzyme as an adjuvant marker for
assessing the inflammatory state of patients with MetS.
Currently, it is already recognized that arterial stiffness
is independently associated with the occurrence of cardio-
vascular events [43, 44]. Among the available parameters for
noninvasively assessing the degree of arterial stiffness, the
AI presents a strong correlation with the gold-standard (the
Pulse Wave Velocity, PWV) for studying aortic stiffness [44],
being an important marker of arterial stiffness [24].
Several studies have demonstrated the increased arte-
rial stiffness in individuals with MetS [7, 45]. The AI
and the PWV, albeit described as markers of vascular
stiffness [44, 46], are not always altered in the same direction.
Kovaite et al. [47] did not find significant difference for the
AI obtained from the radial artery between patients with
and without MetS. Nevertheless, the authors observed an
association between MetS and the increase in PWV [47].
These data, together with those found in the present report
for arterial stiffness, highlight the importance of consider-
ing the methodological approach used for determining the
existence of significant differences between groups, without
overlooking other possible interfering factors. In the current
study, nine patients (37.49%) in the MetS group (Table 2)
were taking angiotensin converting enzyme (ACE) inhibitors
or angiotensin receptor antagonists, a fact that may have, at
some degree, contributed to reduce the effects of the renin-
angiotensin system in the vascular wall. In addition, statins
may reverse abnormalities related to the arterial stiffness
[43, 46]. Also, metformin is associated with reduction in
macrovascular events in patients with diabetes [48]. Thus,
the potential effects of such drugs must be considered when
assessing the vascular stiffness in patients under their use.
More interestingly, the lack of difference between groups
for the AI, a possible indirect means for assessing the
endothelial function [49], was accompanied by similar con-
centrations of nitrite in plasma (also a marker of endothelial
function) [12] in both groups.
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Figure 5: Linear regression analyses between myeloperoxidase (MPO) activity and (a) systolic blood pressure (SBP); (b) diastolic blood
pressure; (c) HDL cholesterol (HDL-c) levels; (d) LDL cholesterol (LDL-c) levels; (e) triglycerides; (f) central obesity; (g) fasting glucose; and
(h) fasting insulin. For LDL-c levels, 𝑛 = 41 because in the MetS group one patient exhibited triglyceride levels greater than 400mg⋅dL−1,
thus impairing the determination of LDL-c levels. For the other parameters assessed, 𝑛 = 42.
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The ∙NO levels in individuals with MetS are rather
conflicting in the literature. Sima˜o et al., in a case-control
study, identified lower concentrations of nitrite/nitrate in the
MetS group, reflecting lower concentrations of ∙NO [50]. In
opposition to these observations, Ueyama et al. [51] showed
that the concentrations of nitrite/nitrate increased when the
number of the MetS diagnostic criteria was progressively
augmented in humans. Such finding was defined as “unex-
pected,” and the authors suggested a possible compensatory
pathway for increasing ∙NO synthesis [51]. Taken together,
such discrepancies may be related to the particularities of
each considered sample, including the time of progression
of the morbid process, and the presence and duration of
pharmacological treatment. In this regard, in the present
report, different drugs with potential to positively interfere
on the endothelial function had been regularly used by
MetS patients, such as ACE inhibitors, angiotensin receptor
antagonists [52], metformin, and statins [53].
For arginase activity, no significant differences were
observed between groups. This enzyme, predominantly
expressed in the liver, kidneys, and erythrocytes, converts
L-arginine to urea and ornithine [54]. Under conditions of
increased arginase activity, a reduction in ∙NO production
may be observed, as such enzyme competes with eNOS for
the same substrate, L-arginine [55]. In situations of metabolic
injury, changes in arginase activity are already described, as
was the casewith the augmented basal serumarginase activity
in diabetic patients compared to controls [54]. The lack of
difference for arginase activity between groups in the current
report may point to the unrepresentative participation of
plasma and erythrocyte arginase in the cardiometabolic
dysregulation observed in the MetS group. It is not possible,
however, to rule out the participation of this enzyme in other
tissue microenvironments not assessed in the present study.
Finally, the exact mechanisms that determine redox
imbalance in MetS in humans have yet to be better dissected,
but our findings give insight into the comprehension of an
enzymatic pathway possibly involved in this process.Thus, we
do believe that this observation may shed some light on the
possibility of pharmacological strategies in order to mitigate
the cardiometabolic derangements found in the course of
MetS.
Some limitations deserve to be mentioned in this study.
Firstly, the relatively small sample size does not ensure that
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the lack of significant difference for some parameters assessed
really occurs in the general population, so that further studies
are required to consider this possibility. Secondly, as an
observational, case-control study, it is not possible to establish
a causal relationship between the variables studied.
5. Perspectives
So far as we are aware, it is the first study pointing to the possi-
ble participation ofMPO in amplifying the oxidative effects of
H
2
O
2
on systemic lipid peroxidation. Once lipoperoxidation
was found to be dependent on the action of MPO, further
studies are warranted to identify other possible contributing
pathways in this process, but our data point toMPO/H
2
O
2
as
a potential therapeutic target in cardiometabolic diseases.
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